证券代码：301017 证券简称：漱玉平民 漱玉平民大药房连锁股份有限公司 投资者关系活动记录表 编号：2023-003 | 答：尊敬的投资者您好，本次交易尚处于筹划阶段，相关工作正 | | --- | | 在有序开展中。公司将根据相关事项的进展情况，及时履行信息 | | 披露义务，敬请广大投资者关注后续进展公告。感谢您的关注。 | | 问题 2、请问公司 4 月底股东人数有多少？ | | 答：截至 年 月底，公司股东人数为 人。 2023 4 10,307 | | 问题 3、请问公司如何提升盈利水平？ | | 答：尊敬的投资者您好，一是随着公司规模的扩大，公司的采购 | | 成本将会逐渐降低；二是公司重点发展高质量、有竞争力的自有 | | 商品矩阵，提升非药产品等高毛利商品的销售占比；三是进一步 | | 细化和加强并购标的的评估和整合，建立专业的并购整合团队， | | 努力提升并购标的的盈利贡献；四是加强对加盟门店的赋能，全 | | 面提升加盟门店的盈利水平。 | | 问题 4、请问公司的对外扩张战略是什么？ | | 答：您好，感谢您对公司的关注！公司将继续坚持"深耕山东， | | 择机走向全国"的发展战略 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示： 特此公告。 漱玉平民大药房连锁股份有限公司 关于举行 2022 年度网上业绩说明会的公告 漱玉平民大药房连锁股份有限公司 董 事 会 2023 年 5 月 5 日 漱玉平民大药房连锁股份有限公司《2022 年年度报告》及摘要已于 2023 年 4 月 27 日 在巨潮资讯网（http://www.cninfo.com.cn）上披露。为了便于投资者进一步了解公司 2022 年度经营情况，公司将于 2023 年 5 月 15 日（星期一）15:30-17:00 举行 2022 年度网上业 绩说明会。本次年度业绩说明将通过深圳证券交易所提供的"互动易"平台举行，投资者 可登录"互动易"网站（http://irm.cninfo.com.cn），进入"云访谈"栏目参与本次年度 业绩说明会。 出席本次业绩说明会的人员有：董事长李文杰先生，董事兼总裁秦光霞女士，董事、 副总裁兼董事会秘书李强先生，财务总监胡钦宏先生，独立董事晏莉女士，保荐代表人朱 彤先生。具体以当天实际参会人员为准。 | 证券代码：301017 ...

证券代码：301017 证券简称：漱玉平民 漱玉平民大药房连锁股份有限公司 投资者关系活动记录表 编号：2023-002 | 投资者关系活动 | □特定对象调研 □分析师会议 | | | --- | --- | --- | | 类别 | □媒体采访  业绩说明会（线上） | | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 | | | 参与单位名称及 | 东北证券 刘宇腾、文将儒 中信证券 陈竹、沈睦钧 兴业证券 | 孙 | | 人员姓名 | 媛媛、王佳慧等投资者共 81 人；华创证券 黄致君、胡婧怡 | 国 | | | 金证券 张玉 天风证券 张文星 国盛证券 张金洋、胡婧怡等投 | | | | 资者共 41 人，共计 122 人。 | | | 时间 | 2023 年 4 月 27 日上午、下午 | | | 地点 | 公司总部会议室（电话会议） | | | 上市公司接待人 | 董事、总裁：秦光霞 | | | 员姓名 | 董事、副总裁、董事会秘书：李强 | | | | 财务总监：胡钦宏 | | | | 公司于 2023年 4月 27日通过线上形式召开投资者电话交流 | ...

Financial Performance - The company's revenue for Q1 2023 reached ¥2,072,482,825.34, representing a 30.56% increase compared to ¥1,587,366,356.60 in the same period last year[4] - Net profit attributable to shareholders was ¥64,553,649.73, up 30.38% from ¥49,513,055.97 year-on-year[4] - The basic and diluted earnings per share increased by 33.33% to ¥0.16 from ¥0.12 in the previous year[11] - In Q1 2023, the company achieved operating revenue of CNY 2,072.48 million, a year-on-year increase of 30.56%[19] - The net profit attributable to shareholders was CNY 64.55 million, reflecting a growth of 30.38% compared to the same period last year[19] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 60.35 million, up 14.28% year-on-year[19] - Net profit for Q1 2023 was ¥66,526,141.25, representing a 34.5% increase from ¥49,492,167.56 in Q1 2022[31] - Operating profit for the quarter was ¥88,553,856.04, up from ¥74,612,400.04, indicating a growth of 18.5% year-over-year[31] Assets and Liabilities - The total assets at the end of the reporting period were ¥8,059,381,246.23, a 2.50% increase from ¥7,863,166,992.04 at the end of the previous year[5] - As of March 31, 2023, total assets amounted to 8,059,381,246.23 CNY, an increase from 7,863,166,992.04 CNY at the beginning of the year[27] - Total liabilities rose to 5,725,138,993.84 CNY from 5,596,102,022.35 CNY, indicating an increase of about 2.3%[28] - The company reported a total equity of 2,296,415,001.54 CNY, up from 2,231,277,500.21 CNY, reflecting an increase of about 2.9%[28] Cash Flow - The net cash flow from operating activities decreased by 9.91% to ¥56,575,234.08 from ¥62,801,486.78 in the same period last year[4] - The company reported a net cash flow from investing activities of -262,700,492.29 CNY, compared to -33,919,646.89 CNY in the previous year[36] - The total cash inflow from financing activities was 51,664,000.00 CNY, down from 163,000,000.00 CNY year-over-year[36] - The net cash flow from financing activities was -282,889,970.43 CNY, a significant decrease from 36,220,433.04 CNY in the same period last year[36] - The net increase in cash and cash equivalents was -489,015,228.64 CNY, compared to an increase of 65,102,272.93 CNY in the previous year[36] - The ending balance of cash and cash equivalents was 1,021,875,903.46 CNY, down from 391,178,131.80 CNY year-over-year[36] Operational Metrics - The company’s gross profit margin improved, with operating costs rising by 33.49% to ¥1,469,857,968.94 due to an increase in store numbers[11] - The company opened 86 new stores and closed 209 stores during the reporting period[19] - As of the end of March 2023, the company operated a total of 6,041 stores, including 3,620 direct-operated stores and 2,421 franchised stores[19] - The company’s direct-operated store distribution includes 3,268 stores in Shandong province[19] - The company maintains a direct chain marketing model and a steady expansion strategy focused on regional development[19] Investments and Financing - The company issued CNY 800 million of convertible bonds on December 15, 2022, with a total issuance amount of CNY 80 million[20] - The convertible bonds began trading on the Shenzhen Stock Exchange on January 6, 2023[20] - The company plans to acquire 60% of Jinan Pingjia Real Estate Co., Ltd. and 90% of Liaoning Tianshili Pharmacy Chain Co., Ltd. through cash payments, currently in the preliminary planning stage[23] Other Financial Information - The company recorded a government subsidy of ¥4,561,774.44, which is closely related to its normal business operations[6] - The company's inventory increased to 2,061,517,554.47 CNY from 1,793,620,391.13 CNY, reflecting a growth of approximately 14.9%[26] - The company’s short-term borrowings decreased to 989,677,435.26 CNY from 1,209,859,212.57 CNY, a reduction of approximately 18.1%[27] - The company’s accounts receivable decreased to 743,322,909.29 CNY from 769,826,716.85 CNY, a decline of about 3.5%[25] - The company’s long-term investments increased slightly to 142,792,812.68 CNY from 141,630,899.74 CNY, showing a growth of approximately 0.8%[26] - The company implemented a restricted stock incentive plan, granting a total of 4.7 million shares at a price of 8.79 CNY per share to 119 incentive targets[21] - The company reported other income of ¥7,322,989.74, which increased from ¥6,810,205.00 in Q1 2022[29] - Investment income from joint ventures and associates was ¥1,161,912.94, a turnaround from a loss of ¥430,424.47 in the previous year[31] Audit Information - The company did not undergo an audit for the first quarter report[37]

Financial Performance - The company's operating revenue for 2022 was ¥7,822,931,715.52, representing a 47.00% increase compared to ¥5,321,639,204.67 in 2021[22] - The net profit attributable to shareholders for 2022 was ¥229,430,842.20, a significant increase of 99.64% from ¥114,924,330.81 in 2021[22] - The net profit after deducting non-recurring gains and losses was ¥220,035,639.01, up 115.18% from ¥102,254,571.67 in the previous year[22] - The basic earnings per share for 2022 was ¥0.57, a 90.00% increase from ¥0.30 in 2021[22] - The total assets at the end of 2022 reached ¥7,863,166,992.04, marking a 57.18% increase from ¥5,002,769,668.71 at the end of 2021[22] - The net assets attributable to shareholders increased by 18.08% to ¥2,231,277,500.21 from ¥1,889,588,905.46 in 2021[22] - The net cash flow from operating activities was ¥148,443,981.75, a decrease of 37.50% compared to ¥237,526,003.92 in 2021[22] - The weighted average return on equity for 2022 was 11.55%, an increase from 6.71% in 2021[22] Market Expansion and Operations - The company expanded its store network to 5,456 locations by the end of 2022, adding 2,115 new stores during the year, including 318 new direct-operated stores and 450 acquired stores[43] - The company operates in multiple provinces including Shandong, Liaoning, Heilongjiang, Fujian, and Henan, expanding its brand influence and market presence[36] - The company has been focusing on developing its wholesale franchise business since the end of 2019 to adapt to industry trends[39] - The company aims to enhance its online sales channels through a combination of B2C and O2O strategies to meet consumer demand for online pharmaceutical purchases[39] - The company is expanding its market presence in northern China, focusing on urban center stores and utilizing big data for site selection and customer flow analysis[62] Product Development and Sales - The company developed a total of 969 SKUs for its proprietary products, achieving a sales growth of 84% year-on-year, accounting for nearly 13% of total retail sales[54] - The "鹊华" brand of traditional Chinese medicine products saw sales increase by over 100% year-on-year due to innovative product development and marketing strategies[66] - New product lines introduced in 2022 contributed to a 25% increase in sales volume, particularly in the health supplement category[160] Financial Management and Investments - The total investment during the reporting period was CNY 839.47 million, a 30.49% increase compared to CNY 643.34 million in the previous year[97] - The company completed significant equity investments totaling approximately RMB 344.84 million during the reporting period[98] - The company raised a total of RMB 108.99502 million through public offerings and convertible bonds, with RMB 20.39 million utilized by the end of the reporting period[103] - The company has a total of RMB 793.5 million remaining in its fundraising account as of December 31, 2022[106] Corporate Governance and Compliance - The company has established a performance evaluation and incentive mechanism for directors, supervisors, and senior management to enhance the effectiveness of performance assessment systems[135] - The company emphasizes investor relations management through various communication methods, including phone calls, online performance briefings, and on-site research[136] - The company has set up an internal audit department to oversee related transactions, external guarantees, and the implementation of internal control systems, ensuring compliance and protecting shareholder rights[138] - The company maintains independence in assets, personnel, finance, institutions, and business operations from its controlling shareholders and actual controllers[139] Social Responsibility and Community Engagement - The company reported a total donation of approximately 17 million yuan for social welfare activities during the reporting period[196] - The company provided over 11 million yuan worth of masks and medical supplies as part of its social responsibility efforts[196] - In December 2022, the company distributed 320,000 acetaminophen tablets for free to pregnant women in Jinan and 6 million ibuprofen tablets benefiting 628,000 people in Shandong Province[196] - The company has established 127 donation points for the "Hope House" charity project, donating over 40,000 books to children in need[197] Employee Management and Development - The total number of employees at the end of the reporting period was 13,270, with 4,548 in the parent company and 8,722 in major subsidiaries[176] - The company has established a comprehensive training system, including various training programs for new employees, in-service staff, and management, to enhance professional skills and service quality[179] - The company plans to implement an employee stock ownership plan to enhance the alignment of interests between employees and owners, improving governance and competitiveness[178]

Financial Performance - The company's revenue for Q3 2022 reached ¥1,857,735,319.22, representing a 50.32% increase compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2022 was ¥18,474,843.69, a decrease of 19.93% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥16,756,842.71, down 15.32% from the previous year[5] - The company's basic earnings per share for Q3 2022 was ¥0.05, a decline of 16.67% compared to the same period last year[5] - Year-to-date revenue reached RMB 5,247.41 million, up 41.25% year-on-year, with a net profit of RMB 130.00 million, an increase of 18.16%[24] - Net profit for the current period was ¥125,663,645.74, up from ¥110,615,002.37 in the previous period, indicating a growth of approximately 13.6%[48] - The company reported a total profit of ¥163,967,010.65 for the current period, compared to ¥146,458,657.10 in the previous period, marking an increase of about 12.0%[48] Assets and Liabilities - Total assets as of September 30, 2022, amounted to ¥6,260,311,061.90, reflecting a 25.14% increase from the end of the previous year[5] - The total assets and owners' equity reached ¥6,260,311,061.90 and ¥2,028,727,340.32 respectively, compared to ¥5,002,769,668.71 and ¥1,914,036,739.95 in the previous period[43] - The company's current liabilities totaled approximately 3.71 billion yuan, up from 2.62 billion yuan at the beginning of the year, reflecting increased borrowing and operational scale[39] - The company's long-term equity investments increased by 63.12% to ¥150,801,444.27 due to acquisitions made during the year[12] - The company's short-term borrowings rose by 85.74% to ¥1,023,063,751.55, driven by increased funding needs[12] Cash Flow - The company's cash flow from operating activities for the year-to-date period was ¥173,063,111.27, showing a slight decrease of 0.37% year-on-year[5] - Cash flow from operating activities was ¥5,285,774,613.04, compared to ¥4,194,835,030.12 in the prior period, showing an increase of approximately 25.9%[52] - Operating cash inflow totaled $5.31 billion, up from $4.22 billion year-over-year, representing a 25.8% increase[55] - Net cash flow from operating activities was $173.06 million, slightly down from $173.71 million year-over-year[55] - Financing cash inflow totaled $894.20 million, compared to $604.27 million in the previous year, marking a 48% increase[58] Shareholder Information - The company has a total of 12,642 common shareholders at the end of the reporting period[16] - Major shareholder Li Wenjie holds 35.17% of the shares, with 142,560,000 shares pledged[16] - Major shareholder Qin Guangxia holds 18.12% of the shares, with 73,440,000 shares pledged[16] - The company plans to lift restrictions on 130,124,807 shares by July 5, 2024, which may impact liquidity[22] Operational Highlights - The company experienced a significant increase in accounts receivable, which rose by 93.79% to ¥602,073,866.46, attributed to the expansion of its store network[12] - As of September 30, 2022, the company had a total of 4,633 stores, including 3,098 direct-operated stores and 1,535 franchised stores, with 251 new stores opened and 276 acquired during the reporting period[26] - The company added 786 franchised stores in the first three quarters of 2022, indicating a strong focus on franchise business development[28] - The sales proportion of DTP products increased from 15.29% in the same period last year to 20.75%, an increase of 5.46 percentage points, resulting in a greater revenue growth than net profit growth due to the lower gross margin of DTP products[26] Strategic Initiatives - The company is focusing on expanding its market presence and developing new products[24] - The company is exploring strategic partnerships and potential acquisitions to enhance growth[24] - The company received approval from the Shenzhen Stock Exchange for its application to issue convertible bonds, indicating potential for future capital raising[29] Cost and Expenses - Total operating costs amounted to ¥5,087,238,933.19, compared to ¥3,573,097,383.25 in the prior period, reflecting an increase of about 42.4%[44] - Cash paid for purchasing goods and services was $3.91 billion, an increase from $3.14 billion year-over-year[55] - Cash paid to employees rose to $736.81 million, compared to $530.89 million in the previous year, reflecting a 38.7% increase[55]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 3,389,677,274.17, representing a 36.73% increase compared to CNY 2,479,085,397.97 in the same period last year[26]. - Net profit attributable to shareholders was CNY 111,527,935.22, up 28.26% from CNY 86,952,437.27 year-on-year[26]. - The basic earnings per share increased to CNY 0.28, reflecting a growth of 16.67% compared to CNY 0.24 in the previous year[26]. - Total assets at the end of the reporting period reached CNY 5,784,353,097.64, a 15.62% increase from CNY 5,002,769,668.71 at the end of the previous year[26]. - The company's net assets attributable to shareholders were CNY 1,971,527,020.68, which is a 4.34% increase from CNY 1,889,588,905.46 at the end of the previous year[26]. - The net cash flow from operating activities was CNY 106,361,081.41, showing a 33.57% increase from CNY 79,626,689.68 in the same period last year[26]. Store Expansion and Operations - The company opened 668 new stores in the first half of 2022, bringing the total number of stores to 4,009[43]. - The company has 2,970 direct-operated stores, with 174 newly built and 225 acquired stores during the reporting period[43]. - The company experienced a temporary decline in business growth due to pandemic-related restrictions, but operations quickly normalized post-mid-May 2022[43]. - Daily store efficiency averaged 6,242 yuan, with daily sales per square meter at 57 yuan across all stores[51]. - The company continues to optimize its store locations and enhance the DTP area in hospitals to improve patient access to medications[57]. Market and Industry Insights - The retail pharmacy industry in China saw a market size of CNY 469.6 billion in 2021, with a year-on-year growth of 3.21%[37]. - The chain pharmacy concentration rate reached 57.17% by the end of Q3 2021, an increase of 0.67 percentage points from 2020[38]. - The online and offline business segments grew significantly, with increases of 130.71% and 103.24% respectively in 2021[42]. Revenue Streams and Product Development - The company reported a 186.6% year-on-year increase in wholesale revenue from franchise stores in the first half of 2022, with 1,039 franchise stores signed by the end of the reporting period[53]. - The DTP sales revenue exceeded 570 million yuan, representing a year-on-year growth of 84.13%[54]. - Online business revenue surpassed 360 million yuan in the first half of 2022, with third-party B2C platforms accounting for 39% and third-party O2O platforms for 53% of total transactions[58]. - The company has developed nearly 900 SKUs of private label products, with sales increasing by 70% year-on-year, making up over 11% of total retail sales[59]. Financial Management and Investments - The total investment amount during the reporting period was CNY 201,546,400, representing a 1,048.41% increase compared to CNY 17,550,000 in the same period last year[97]. - The company reported a total of CNY 29,936.61 million in raised funds, with CNY 4,364.42 million utilized during the reporting period[99]. - The marketing network construction project has a total investment commitment of CNY 49,712.66 million, with CNY 3,636.80 million invested during the reporting period, achieving 61.71% of the planned investment progress[104]. - The pharmaceutical chain information service platform project has a total investment commitment of CNY 6,274.48 million, with CNY 727.62 million invested during the reporting period, achieving 91.61% of the planned investment progress[104]. Risk Management and Compliance - The company faces various risks including macroeconomic and market risks, which are detailed in the management discussion section of the report[6]. - The company emphasizes the importance of investor awareness regarding potential investment risks associated with forward-looking statements[5]. - The company is committed to monitoring and adapting to industry policy changes to mitigate operational risks[124]. - The company has maintained a focus on environmental responsibility and has not faced any administrative penalties related to environmental issues during the reporting period[144]. Shareholder and Governance Matters - The number of shareholders was 4,662, with 2,230,807 shares released from restrictions, accounting for 0.55% of the total share capital[170]. - The company approved a cash dividend of CNY 0.73 per 10 shares, totaling CNY 29,589,820.00 distributed to shareholders[177]. - The total share capital of the company is 405,340,000 shares, with 91.11% being restricted shares prior to the recent changes[186]. - The largest shareholder, Li Wenjie, holds 35.17% of the shares, amounting to 142,560,000 shares, with 3,700,000 shares pledged[197]. Employee and Community Engagement - The company has actively donated over 11 million RMB in pandemic relief materials and funds during the first half of 2022, including over 4 million RMB to the Shandong Provincial Disabled Persons Welfare Foundation[145]. - The company has implemented a comprehensive recruitment plan and expanded multi-channel recruitment to attract high-level management and professional pharmaceutical talents[130]. - The company has established a mobile learning platform to enhance employee competency across various positions[130]. - The company actively participated in pandemic prevention efforts, establishing a nucleic acid testing "strike team" with nearly 100 medical professionals[148].

Financial Performance - The company's revenue for Q1 2022 was CNY 1,587,366,356.60, representing a 33.99% increase compared to CNY 1,184,719,395.97 in the same period last year[6] - Net profit attributable to shareholders was CNY 49,513,055.97, up 31.61% from CNY 37,620,141.84 year-on-year[6] - The net profit after deducting non-recurring gains and losses increased by 61.60% to CNY 52,812,577.93 from CNY 32,681,017.38 in the previous year[6] - In Q1 2022, the company achieved revenue of RMB 158.74 million, a year-on-year increase of 33.99%[25] - The net profit attributable to shareholders was RMB 49.51 million, up 31.61% year-on-year, while the net profit excluding non-recurring gains and losses reached RMB 52.81 million, a growth of 61.60%[25] - Total operating revenue for the current period reached ¥1,587,366,356.60, an increase of 34.0% compared to ¥1,184,719,395.97 in the previous period[44] - Net profit for the current period was ¥49,492,167.56, representing a 34.3% increase from ¥36,792,571.21 in the previous period[47] - The company reported a total comprehensive income of ¥49,513,055.97 for the current period, compared to ¥37,620,141.84 in the previous period[51] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 5,423,578,891.92, an increase of 8.41% from CNY 5,002,769,668.71 at the end of the previous year[6] - As of the end of the first quarter of 2022, total assets reached approximately 5.42 billion yuan, up from 5.00 billion yuan at the beginning of the year[36] - Total liabilities amounted to ¥3,457,049,984.41, an increase from ¥3,088,732,928.76 in the previous period[43] - Total current liabilities rose to approximately 2.94 billion yuan from 2.62 billion yuan at the beginning of the year[39] - Total equity attributable to shareholders of the parent company was ¥1,939,101,961.43, up from ¥1,889,588,905.46 in the previous period[43] Cash Flow - Cash flow from operating activities decreased by 29.81% to CNY 62,801,486.78 from CNY 89,476,310.51 in the same period last year[6] - The net cash flow from operating activities was $62,801,486.78, a decrease of 29.8% compared to $89,476,310.51 in the previous period[55] - Cash inflow from investment activities totaled $126,745,211.23, significantly up from $3,063,272.37 in the prior period[55] - The net cash flow from financing activities was $36,220,433.04, recovering from a negative cash flow of $59,928,655.50 in the previous period[58] - The total cash and cash equivalents at the end of the period reached $391,178,131.80, an increase from $275,441,682.73 at the end of the previous period[58] - The company experienced a net increase in cash and cash equivalents of $65,102,272.93, contrasting with a decrease of $1,871,785.51 in the previous period[58] Operational Highlights - The number of accounts receivable increased by 44.74% to CNY 449,690,316.30, primarily due to an increase in store numbers and corresponding receivables[9] - The company's sales expenses rose by 47.93% to CNY 355,006,042.45, attributed to the increase in store numbers[13] - Financial expenses surged by 121.40% to CNY 13,832,467.08, mainly due to the amortization of lease interest expenses under new leasing standards[13] - The company reported a significant increase in investment income, which rose by 276.44% to CNY 2,150,297.68 from a loss of CNY 1,218,688.70 in the previous year[13] - Prepayments increased by 256.67% to CNY 16,007,495.21, primarily due to an increase in prepaid rent[9] - The DTP business recorded a sales revenue of RMB 263 million, representing a year-on-year increase of 68.58%[27] - The company’s new retail strategy led to over RMB 160 million in revenue from third-party B2C and O2O platforms, a growth of 72.5% year-on-year[27] Expansion and Acquisitions - The company expanded its store count to 3,686 by the end of the reporting period, with 2,897 direct-operated stores and 789 franchised stores[26] - The company signed 40 new franchise agreements in Q1 2022, bringing the total number of franchised stores to 789[28] - The company opened 100 new stores across various regions during the reporting period[26] - The company aims to strengthen its presence in northern China, covering provinces such as Liaoning, Heilongjiang, and Henan[30] - The company established a wholly-owned subsidiary in Harbin, Heilongjiang Province, completing business registration on January 18, 2022[31] - The acquisition of 54 stores from Zibo Renjitang by the company's subsidiary Zibo Shuyu Pharmacy was completed in January 2022, enhancing market share in Zibo, Shandong Province[31] - The company’s subsidiary Dongying Yishengtang acquired all operating assets of Dongying Shuyu, integrating 22 stores to improve market concentration in Dongying City[32] - The company and its subsidiary Tai'an Shuyu jointly purchased operational assets from Pingyin Shennong Pharmacy, completed in March 2022, to strengthen market presence in Pingyin County, Jinan City[32] - The company increased its stake in Harbin Baofeng Pharmacy from 10% to 19% by acquiring an additional 9% equity, completed on March 23, 2022[33] - The company purchased 51% equity in Fujian Huibaixing for no more than 50 million yuan, completing the transaction on March 24, 2022[33] - The company acquired 51% equity in Fujian Juzhilin for no more than 40 million yuan, with the transaction completed on March 25, 2022[33] Employee and Operational Costs - Cash outflow for purchasing goods and services was $1,073,255,204.99, up from $880,015,936.49 in the prior period, reflecting increased operational costs[55] - The company paid $238,491,082.66 to employees, which is an increase from $171,130,910.28 in the prior period, reflecting higher payroll expenses[55]

Group 1: Event Announcement - Shuyupingmin Pharmacy Chain Co., Ltd. will participate in the 2021 Annual Investor Online Reception Day organized by Shandong Securities Regulatory Bureau and Shandong Listed Companies Association [2] - The event will take place on November 16, 2021, from 14:00 to 16:00 [2] Group 2: Communication Details - The online platform for the event is provided by Shenzhen Qianjing Network Co., Ltd., accessible via "Qianjing·Roadshow World" website [2] - Company representatives, including Vice President Li Qiang, CFO Hu Qinhong, and Securities Affairs Representative Qi Yanli, will engage with investors online [2] Group 3: Commitment to Transparency - The company and its board members guarantee the accuracy and completeness of the disclosed information, ensuring no false statements or significant omissions [2]

Financial Performance - The company's revenue for Q3 2021 reached ¥1,235,833,319.92, an increase of 13.57% compared to the same period last year[2]. - Net profit attributable to shareholders decreased by 55.83% to ¥23,072,606.54, while the net profit excluding non-recurring gains and losses fell by 52.20% to ¥19,788,874.58[2][5]. - Basic and diluted earnings per share both dropped by 57.14% to ¥0.06[2][6]. - Total operating revenue for Q3 2021 reached CNY 3,714,918,717.89, an increase of 11.4% compared to CNY 3,336,560,975.81 in the same period last year[27]. - Net profit for Q3 2021 was CNY 110,615,002.37, a decrease of 11.1% from CNY 124,404,105.77 in the previous year[28]. Assets and Liabilities - Total assets increased by 41.10% to ¥4,339,402,536.19, primarily due to the implementation of new leasing standards and expansion of business operations[6]. - The company's total liabilities increased to CNY 2,444,582,538.49, compared to CNY 1,545,243,705.35 in the same period last year, representing a growth of 58.2%[26]. - Current liabilities rose to CNY 305,006,323.61, up from CNY 108,106,323.61 at the end of 2020[24]. - The total amount of accounts payable increased to CNY 801,675,742.87 from CNY 592,302,832.33, reflecting a rise of 35.4%[25]. Cash Flow - Cash flow from operating activities showed a slight decrease of 0.19% to ¥173,708,387.88[2]. - The net cash flow from operating activities for Q3 2021 was CNY 173,708,387.88, slightly down from CNY 174,040,434.87 in Q3 2020, indicating a decrease of 0.19%[31]. - The total cash outflow from investing activities was CNY 351,213,735.97, compared to CNY 180,684,650.07 in the previous year, representing an increase of 94.5%[31]. - The net cash flow from financing activities increased significantly to CNY 277,387,091.51 from a negative CNY 4,458,124.06 in Q3 2020, showing a turnaround in financing strategy[31]. Store Expansion and Workforce - A total of 137 new stores were added during the reporting period, representing a year-on-year increase of 280.56%[14]. - Cumulatively, 413 new stores were opened in the first three quarters of the year, a 344.09% increase compared to the same period last year[14]. - The company increased its workforce by 1,572 employees during the reporting period, a 205.84% increase year-on-year[15]. - Cumulative employee growth for the first three quarters reached 2,362, up 275.52% from the previous year[15]. Income and Expenses - Financial expenses rose significantly by 203.70% to ¥18,147,675.75, mainly due to the amortization of leasing interest expenses[8]. - The company reported a substantial increase in other income by 186.96% to ¥12,896,710.83, driven by tax reductions and other subsidies[8]. - Cash paid for dividends and interest increased by 149.36% to ¥51.01 million, attributed to last year's dividends[9]. Business Operations - The company is expanding its marketing network through self-built and acquired stores, focusing on deepening its presence in Shandong and exploring national expansion[15]. - DTP business sales reached CNY 187 million in the reporting period, representing a year-on-year growth of 35.71%[18]. - Online sales surged to CNY 143 million, a 73.4% increase year-on-year, with O2O sales accounting for 63.3% of total online sales[18]. Investments and Acquisitions - The company established a new pharmaceutical industrial park in Zaozhuang with a registered capital of CNY 50 million[19]. - The company invested CNY 1,050,000 in the bankruptcy reorganization of Huangshan Huizhao Medicine Co., acquiring 100% equity[20]. - The company plans to acquire 100% equity of Qihe Taiyao Enterprise Management Co., Ltd. for up to CNY 288 million[21]. Regulatory and Reporting - The third quarter report has not been audited[36]. - The new lease accounting standards were first implemented in 2021, with retrospective adjustments made to prior comparative data[36].